Wei-Qing Zhao

Wei-Qing Zhao

Auto-generated profile, based on publicly available information

Wei-Qing Zhao

Departments of Oncology, the Third Affiliated Hospital of Soochow University, Changzhou, 213003, China

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2014 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
HSHongbing Shi
Hongbing Shi
MJMei Ji
Mei Ji
WHWenwei Hu
Wenwei Hu
QZQi Zhou
Qi Zhou
XLXiaodong Li
Xiaodong Li
JJJingting Jiang
Jingting Jiang
B7-H4 is a novel B7 ligand that plays an important role in the T cell-mediated immune response as a negative regulator. Previous studies have suggested the aberrant expression of membrane B7-H4 in tumor cells. The aim of this study is to determine the expression levels of preoperative soluble B7-H4 (sB7-H4) in circulation and to investigate the correlations between sB7-H4 levels and clinicopathological parameters as well as the survival rate of patients with gastric cancer. Blood specimens from 132 patients with gastric cancer and 63 healthy volunteers were analyzed by sandwich enzyme-linked immunosorbent assay. Median concentrations of sB7-H4 in patients with gastric cancer were significantly higher than those in healthy volunteers (16.85 versus 10.46 ng/mL; P = 0.008). Median levels of sB7-H4 were significantly correlated with tumor size, lymph node metastasis, the depth of tumor invasion and tumor-node-metastasis classification (P = 0.002, P = 0.001, P = 0.041 and P 0.05). Additionally, the overall survival rate was significantly lower in patients with high sB7-H4 levels when compared with low sB7-H4 levels (50.0% versus 77.3%, χ2 = 10.78, P = 0.001). Moreover, multivariate analysis demonstrated that the risk of death was significantly higher in patients with high sB7-H4 levels than in those with low sB7-H4 levels (P = 0.039). sB7-H4 is a valuable blood marker for predicting the progression and prognosis of patients with gastric cancer.

16 October 2019 in BMC Medical Genomics
Verified
Journal Article
Open access
PDF file
CFCheng Fang
Cheng Fang
CZChu Zhang
Chu Zhang
WZWei-Qing Zhao
Wei-Qing Zhao
WHWen-Wei Hu
Wen-Wei Hu
JWJun Wu
Jun Wu
MJMei Ji
Mei Ji
Background: Unprecedented durable responses are identified in clinical studies to target the signaling of programmed cell death protein-1 (PD-1) as well as its ligand (PD-L1) in patients with squamous-cell non-small cell lung cancer (NSCLC). However, factors predicting the patient subtypes that are responsive to PD-1/PD-L1inhibitors have not been fully understood yet. Biomarkers, like PD-L1 expression, tumor mutational burden(TMB), DNA mismatch repair deficiency (dMMR), and tumor-infiltrating lymphocytes (TILs), have been utilized to select patients responsive to PD-1/PD-L1inhibitors in the clinic, but each of them has limited use. Lung adenocarcinoma patients with a mutation of TP53 or KRAS, particularly those with co-mutations of TP53 and KRAS, can benefit from anti–PD-1 treatment.Case presentation: In this study, the co-mutations of TP53 and KRAS in a 64-year-old non-smoking man with squamous-cell NSCLC patient was described using the next-generation sequencing (NGS) technology. The patient was treated with the pembrolizumab combined with gemcitabine as the salvage therapy, and a marked partial response could be attained, which had persisted for over 7 months.Conclusion: In addition to testing common driving genes, like EGFR, ALK, ROS1 and BRAF, both TP53, and KRAS should also be considered in advanced or metastatic squamous-cell NSCLC.TP53 and KRAS co-mutations in squamous-cell NSCLC can be a potential factor to assess possible response to PD-1 blockade immunotherapy, but further studies with more cases are needed to confirm the prediction power.

28 May 2014 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
WZWei-Qing Zhao
Wei-Qing Zhao
XLXiaodong Li
Xiaodong Li
HSHongbing Shi
Hongbing Shi
JWJun Wu
Jun Wu
JZJiaming Zhang
Jiaming Zhang
CWChang-Ping Wu
Chang-Ping Wu
We aimed to detect CD40 mutant expression and evaluate its clinical significance in gastric cancer.